Thyroid Cancer Surgery: “Less is More” in the Light of ATA 2025

Abstract

The management of differentiated thyroid cancer (DTC) has undergone a significant paradigm shift from aggressive surgical intervention toward a more individualized and conservative approach. The 2025 American Thyroid Association (ATA) guidelines reinforce the principle of “less is more,” emphasizing risk-adapted, patient-centered care while minimizing overtreatment in low-risk disease. This commentary reviews the evolving surgical strategies in thyroid cancer including the expanding role of thyroid lobectomy, selective use of radioactive iodine, avoidance of routine prophylactic central neck dissection, acceptance of active surveillance for low-risk papillary thyroid microcarcinoma, molecular profiling and a more cautious approach to completion thyroidectomy. The 2025 guidelines introduce the DATA framework (Diagnosis, risk/benefit assessment, treatment decisions, and response assessment) to promote dynamic, individualized management that integrates histopathology, imaging, and selective molecular markers without over-reliance on single mutations (e.g., BRAFV600E alone). Collectively, 2025 ATA prioritizes oncologic safety, reduced morbidity, and patient-centered outcomes through conservative surgery, selective nodal management, and more restrictive RAI use.